Biotech News

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

IceCure Medical (ICCM)IceCure Medical2026-06-25 13:46 ESTEarnings

ICCM (ICCM) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is iccm.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

ICCMIceCure Medical2026-06-25 13:46 EST

IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

ICCMIceCure Medical2026-06-25 13:46 EST

IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer

ICCMIceCure Medical2026-06-25 13:46 EST

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

ICCMIceCure Medical2026-06-25 13:46 EST

IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance

ICCMIceCure Medical2026-06-25 13:46 EST

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

ICCMIceCure Medical2026-06-25 13:46 EST

IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked

ICCMIceCure Medical2026-06-25 13:46 EST

IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

ICCMIceCure Medical2026-06-25 13:46 EST

American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer

ICCMIceCure Medical2026-06-25 13:46 EST

IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026

ICCMIceCure Medical2026-06-25 13:46 EST

U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer

View all latest news

IceCure Medical

IceCure Medical is a medical devices company focused on product adoption, procedure volume, and how clinical workflow converts into recurring demand.

Recent company news

ICCMIceCure Medical2026-06-26 10:58 EST

IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

ICCMIceCure Medical2026-06-26 10:58 EST

IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer

ICCMIceCure Medical2026-06-26 10:58 EST

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

ICCMIceCure Medical2026-06-26 10:58 EST

IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance

ICCMIceCure Medical2026-06-26 10:58 EST

IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States